title: Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program.
abstract: BACKGROUND
  In March, 2006, oral rotavirus vaccine was added to Brazil's infant immunization schedule with recommended upper age limits for initiating (by age 14 weeks) and completing (by age 24 weeks) the two-dose series to minimize age-specific risk of intussusception following rotavirus vaccination. Several years after introduction, estimated coverage with rotavirus vaccine (83%) was lower compared to coverage for other recommended childhood immunizations (≥94%).
  
  
  METHODS
  We analyzed data from Brazil's national immunization program on uptake of oral rotavirus vaccine by geographic region and compared administrative coverage estimates for first and second doses of oral rotavirus vaccine (Rota1 and Rota2) with first and second doses of diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine (DTP-Hib1 and DTP-Hib2). For 27 Brazilian cities, we compared differences between estimated rotavirus and DTP-Hib coverage in 2010 with delayed receipt of DTP-Hib vaccine among a cohort of children surveyed before rotavirus introduction.
  
  
  RESULTS
  In 2010, infant vaccination coverage was 99.0% for DTP-Hib1 versus 95.2% for Rota1 (3.8% difference), and 98.4% for DTP-Hib2 versus 83.0% for Rota2 (15.4% difference), with substantial regional variation. Differences between DTP-Hib and rotavirus vaccination coverage in Brazilian cities correlated with delay in DTP-Hib vaccination among children surveyed. Age restrictions for initiating and completing the rotavirus vaccination series likely contributed to lower coverage with rotavirus vaccine in Brazil.
  
  
  CONCLUSIONS
  To maximize benefits of rotavirus vaccination, strategies are needed to improve timeliness of routine immunizations; monitoring rotavirus vaccine uptake and intussusception risk is needed to guide further recommendations for rotavirus vaccination.
authors: US Centers for Disease Control and Prevention, Atlanta, GA 30333, United States. bflannery@cdc.gov
authors: Brendan
authors: B
authors: Flannery
authors: Samia
authors: S
authors: Samad
authors: José Cássio
authors: JC
authors: de Moraes
authors: Jacqueline E
authors: JE
authors: Tate
authors: M Carolina
authors: MC
authors: Danovaro-Holliday
authors: Lúcia Helena
authors: LH
authors: de Oliveira
authors: Jeanette J
authors: JJ
authors: Rainey
mesh_terms: D001938:Brazil; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage; D018073:Haemophilus Vaccines / Q000008:administration & dosage; D006193:Haemophilus influenzae; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D008562:Membrane Glycoproteins; D012401:Rotavirus; D022243:Rotavirus Vaccines / Q000008:administration & dosage*; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D008562:Membrane Glycoproteins; D022243:Rotavirus Vaccines; C055764:S-layer proteins; C080881:diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine